Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...